HB-EGF (Heparin-Binding EGF-Like Growth Factor)

Iwamoto, Ryo; Mekada, Eisuke; Hofmann, Thomas G.; Krieghoff-Henning, Eva; Kobayashi, Mariko; Takamatsu, Ken; Defren, Jennifer; Brewer, Gary; Kaja, Simon; Payne, Andrew J.; Burroughs, Stephanie L.; Koulen, Peter; Königsberger, Sebastian; Kiefer, Friedemann

doi:10.1007/978-1-4419-0461-4_127

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR has seven corresponding ligands: EGF, transforming growth factor-α (TGFα), amphiregulin, betacellulin (BTC), epiregulin, epigen, and heparin-binding EGF-like growth factor (HB-EGF). After ligands bind to EGFR, the autophosphorylation of EGFR can activate the downstream MAPK, Akt, and JNK pathways and promote cell proliferation (Iwamoto and Mekada, 2012).…”

Section: Epidermal Growth Factormentioning

confidence: 99%

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin that usually results in death from secondary respiratory failure within 2–5 years of diagnosis. Recent studies have identified key roles of cytokine and growth factor pathways in the pathogenesis of IPF. Although there have been numerous clinical trials of drugs investigating their efficacy in the treatment of IPF, only Pirfenidone and Nintedanib have been approved by the FDA. However, they have some major limitations, such as insufficient efficacy, undesired side effects and poor pharmacokinetic properties. To give more insights into the discovery of potential targets for the treatment of IPF, this review provides an overview of cytokines, growth factors and their signaling pathways in IPF, which have important implications for fully exploiting the therapeutic potential of targeting cytokine and growth factor pathways. Advances in the field of cytokine and growth factor pathways will help slow disease progression, prolong life, and improve the quality of life for IPF patients in the future.

show abstract

Section: Epidermal Growth Factormentioning

confidence: 99%

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Receptor-Mediated Enhanced Cellular Delivery of Nanoparticles Using Recombinant Receptor-Binding Domain of Diphtheria Toxin

2016

View full text Add to dashboard Cite

Antibodies and peptides are often used to home nanoparticles (NPs) to specific cells. Here in this work, we have used recombinant receptor-binding domain of diphtheria toxin (RDT) as a homing molecule for NPs. Diphtheria toxin binds to heparin binding EGF-like growth factor (HB-EGF) through its receptor-binding domain. HB-EGF is often overexpressed as cell surface molecule in various types of cancer. We have prepared monodispersed, spherical PLGA NPs and coated these NPs with RDT. These NPs are characterized by FESEM and FT-IR spectroscopy. Using flow cytometry and fluorescence spectroscopy, we show that coating with RDT increases cellular uptake of PLGA NPs. We further show that RDT-coated nanoparticles are internalized through clathrin-dependent receptor-mediated endocytosis that can be reduced by specific inhibitor. These RDT-coated nanoparticles (RDT-NP) were further used for preferential delivery of Irinotecan, a chemotherapeutic agent, to cells overexpressing HB-EGF. We show that receptor-mediated enhanced uptake of RDT-NPs increases the potency of irinotecan in these cells.

show abstract

HB-EGF (Heparin-Binding EGF-Like Growth Factor)

Cited by 2 publications

References 29 publications

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Receptor-Mediated Enhanced Cellular Delivery of Nanoparticles Using Recombinant Receptor-Binding Domain of Diphtheria Toxin

Contact Info

Product

Resources

About